This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
influenza virus | 559 |
influenza viruses | 454 |
pandemic influenza | 324 |
respiratory viruses | 270 |
respiratory tract | 255 |
seasonal influenza | 246 |
public health | 211 |
acute respiratory | 210 |
avian influenza | 209 |
hong kong | 178 |
respiratory syncytial | 150 |
influenza vaccine | 150 |
respiratory infections | 146 |
influenza pandemic | 138 |
syncytial virus | 137 |
rrt pcr | 136 |
virus infection | 125 |
lower respiratory | 120 |
influenza vaccination | 114 |
influenza infection | 111 |
swine influenza | 99 |
respiratory virus | 92 |
respiratory syndrome | 91 |
highly pathogenic | 86 |
gene rrt | 84 |
respiratory illness | 83 |
influenza surveillance | 81 |
human influenza | 80 |
tract infections | 79 |
reproduction number | 79 |
health care | 78 |
united states | 76 |
years old | 74 |
risk factors | 74 |
amino acid | 73 |
immune response | 72 |
viral infections | 72 |
respiratory infection | 72 |
world health | 71 |
hospitalized children | 71 |
severe acute | 70 |
human bocavirus | 70 |
mdck cells | 67 |
health organization | 66 |
young children | 66 |
respir viruses | 65 |
cell culture | 64 |
influenza vaccines | 63 |
infected cells | 62 |
viral respiratory | 62 |
medical masks | 61 |
like illness | 61 |
pcr assay | 60 |
human metapneumovirus | 59 |
influenza season | 59 |
viruses doi | 59 |
respiratory pathogens | 59 |
virus infections | 58 |
doc id | 57 |
virus replication | 57 |
cord uid | 57 |
pathogenic avian | 56 |
viral load | 55 |
acquired pneumonia | 55 |
time pcr | 54 |
age groups | 52 |
infectious diseases | 52 |
respiratory viral | 52 |
hrv ent | 51 |
viruses isolated | 51 |
global influenza | 50 |
vaccine virus | 49 |
hpai viruses | 48 |
tract infection | 48 |
middle east | 47 |
surveillance system | 47 |
previously described | 47 |
logistic regression | 46 |
significantly higher | 46 |
viral shedding | 46 |
chain reaction | 46 |
respiratory symptoms | 45 |
surveillance data | 45 |
ae log | 44 |
upper respiratory | 44 |
vaccination coverage | 44 |
vaccine strain | 44 |
real time | 44 |
disease control | 44 |
healthcare workers | 43 |
ae days | 43 |
virus isolation | 43 |
disease severity | 43 |
polymerase chain | 43 |
pandemic virus | 43 |
virus selection | 42 |
immune responses | 42 |
epithelial cells | 42 |
first wave | 42 |
intensive care | 42 |
among children | 42 |
east respiratory | 41 |
human respiratory | 41 |
antibody response | 41 |
human rhinovirus | 41 |
viral infection | 41 |
children aged | 41 |
confirmed cases | 40 |
recovery delay | 40 |
southern hemisphere | 40 |
age group | 40 |
time rt | 40 |
reverse transcription | 40 |
respiratory disease | 40 |
may also | 39 |
north american | 39 |
clinical specimens | 38 |
systematic review | 38 |
severe disease | 38 |
median age | 37 |
new zealand | 37 |
vaccine viruses | 36 |
ci ae | 36 |
gene segments | 36 |
virus isolates | 36 |
clinical characteristics | 36 |
clinical samples | 35 |
pcr assays | 35 |
samples collected | 35 |
viral rna | 35 |
weight loss | 35 |
study period | 34 |
time series | 34 |
viral particles | 34 |
infection control | 33 |
parainfluenza virus | 33 |
applied biosystems | 33 |
ha gene | 33 |
factors associated | 33 |
present study | 33 |
parainfluenza viruses | 33 |
pandemic preparedness | 33 |
fast set | 33 |
secondary cases | 32 |
phylogenetic analysis | 32 |
ae versus | 32 |
common respiratory | 32 |
hospitalized patients | 32 |
syndrome coronavirus | 32 |
statistically significant | 32 |
nasal swabs | 32 |
care workers | 31 |
pandemic vaccine | 31 |
severe respiratory | 31 |
positive samples | 31 |
least one | 31 |
novel influenza | 31 |
symptom onset | 31 |
performed using | 30 |
hand hygiene | 30 |
antiviral drugs | 30 |
respiratory samples | 30 |
chicken eggs | 30 |
southern china | 30 |
pandemic potential | 30 |
acute lower | 30 |
antibody titers | 30 |
north america | 29 |
antiviral treatment | 29 |
versus ae | 29 |
national institute | 29 |
multiplex pcr | 29 |
origin influenza | 29 |
significant difference | 28 |
disease burden | 28 |
serial interval | 28 |
epidemic curve | 28 |
influenza seasons | 28 |
influenza transmission | 28 |
antibody responses | 28 |
household transmission | 28 |
asthmatic patients | 27 |
sore throat | 27 |
vaccine effectiveness | 27 |
reverse genetics | 27 |
early detection | 27 |
body weight | 27 |
aged years | 27 |
adjuvanted vaccine | 27 |
previous studies | 27 |
live attenuated | 27 |
ae lg | 27 |
serum samples | 27 |
pdm virus | 27 |
bioaerosol sampler | 27 |
school closure | 26 |
cell cultures | 26 |
antigenic drift | 26 |
antigenic cartography | 26 |
general practice | 26 |
care unit | 26 |
viral pathogens | 26 |
influenza epidemic | 26 |
case definition | 26 |
time reverse | 26 |
human coronavirus | 25 |
virus strains | 25 |
virus transmission | 25 |
influenza strains | 25 |
turning point | 25 |
embryonated chicken | 25 |
vaccine production | 25 |
flu rsv | 25 |
throat swabs | 25 |
nasopharyngeal swab | 25 |
cleavage site | 25 |
significant differences | 25 |
sample size | 25 |
virus titers | 24 |
cell lines | 24 |
higher risk | 24 |
mdck pf | 24 |
general population | 24 |
virus ns | 24 |
ent infections | 23 |
detection rate | 23 |
clinical data | 23 |
circulating viruses | 23 |
viral replication | 23 |
influenza epidemics | 23 |
internal genes | 23 |
cell index | 23 |
ae ae | 23 |
influenza programme | 23 |
respiratory failure | 23 |
na genes | 23 |
viruses detected | 23 |
study design | 23 |
nucleic acid | 22 |
viruses circulating | 22 |
cystic fibrosis | 22 |
informed consent | 22 |
passive immunotherapy | 22 |
nasal washes | 22 |
clinical signs | 22 |
viral loads | 22 |
cytopathic effect | 22 |
ct values | 21 |
bacterial infection | 21 |
viral etiology | 21 |
syndromic surveillance | 21 |
ae ml | 21 |
important role | 21 |
emergency department | 21 |
statistical analysis | 21 |
illness onset | 21 |
inactivated influenza | 21 |
respiratory distress | 21 |
respirator use | 21 |
sputum samples | 21 |
surveillance systems | 21 |
cell death | 21 |
high yield | 21 |
vp vp | 21 |
mdck cell | 21 |
infectious disease | 21 |
primary care | 21 |
virus detection | 21 |
human macrophages | 21 |
hbov infection | 20 |
isolation rate | 20 |
reverse transcriptase | 20 |
human seasonal | 20 |
laboratory testing | 20 |
log tcid | 20 |
nasopharyngeal swabs | 20 |
within days | 20 |
resistant viruses | 20 |
secondary bacterial | 20 |
social distancing | 20 |
significantly lower | 20 |
transmission dynamics | 20 |
different viruses | 20 |
incubation period | 20 |
urinary antigen | 20 |
like swine | 20 |
pathogen patients | 20 |
set infa | 20 |
cohort study | 20 |
selection process | 20 |
streptococcus pneumoniae | 20 |
medical mask | 20 |
confirmed influenza | 20 |
vaccine candidates | 20 |
dual pathogens | 20 |
children hospitalized | 20 |
control group | 19 |
ic values | 19 |
closely related | 19 |
na gene | 19 |
icu admission | 19 |
tested positive | 19 |
chicken embryos | 19 |
significantly different | 19 |
among hospitalized | 19 |
total number | 19 |
standard deviation | 19 |
within hours | 19 |
distress syndrome | 19 |
pandemic strain | 19 |
neuraminidase inhibitors | 19 |
pdm viruses | 19 |
patients admitted | 19 |
growth rate | 19 |
bacterial infections | 19 |
virus infected | 19 |
hpai virus | 19 |
oseltamivir resistance | 19 |
reproductive number | 19 |
human transmission | 19 |
significantly associated | 19 |
blood samples | 19 |
pandemic wave | 19 |
infection rate | 19 |
ili cases | 19 |
sari cases | 19 |
human parainfluenza | 18 |
severe cases | 18 |
like viruses | 18 |
sentinel ducks | 18 |
influenza pandemics | 18 |
general practitioners | 18 |
direct contact | 18 |
resistant virus | 18 |
index case | 18 |
wild birds | 18 |
slightly lower | 18 |
case data | 18 |
swab specimens | 18 |
migratory ducks | 18 |
regression analysis | 18 |
care facilities | 18 |
circulating influenza | 18 |
sample collection | 18 |
school students | 18 |
air pollution | 18 |
control measures | 18 |
new influenza | 18 |
neuraminidase inhibitor | 18 |
severe bronchiolitis | 18 |
two groups | 18 |
ex vivo | 18 |
vaccination status | 18 |
day post | 18 |
results suggest | 18 |
genetic characteristics | 18 |
severe influenza | 18 |
mexico city | 18 |
tm assay | 18 |
attenuated influenza | 18 |
classical swine | 18 |
fluor tm | 18 |
candidate vaccine | 18 |
confirmed case | 18 |
transcription polymerase | 18 |
infection rates | 18 |
developing countries | 18 |
mean gt | 18 |
pf cells | 18 |
ffp respirators | 17 |
respiratory specimens | 17 |
ae ng | 17 |
clinical trials | 17 |
mean si | 17 |
laiv candidates | 17 |
na mutation | 17 |
antiviral drug | 17 |
respiratory protection | 17 |
days post | 17 |
confidence interval | 17 |
clinical practice | 17 |
clinical disease | 17 |
national influenza | 17 |
virus detected | 17 |
clinical symptoms | 17 |
infections among | 17 |
clinical features | 17 |
influenza infections | 17 |
swine origin | 17 |
higher rates | 17 |
inclusion criteria | 17 |
animal influenza | 17 |
sequence data | 17 |
high risk | 17 |
influenza outbreaks | 17 |
antigen test | 17 |
sequence analysis | 17 |
patients infected | 17 |
attack rate | 17 |
recent years | 17 |
innate immune | 17 |
viral culture | 17 |
ae lm | 16 |
canine kidney | 16 |
ethics committee | 16 |
human cases | 16 |
monocyte cultures | 16 |
infected pigs | 16 |
positive patients | 16 |
rna extraction | 16 |
bronchoalveolar lavage | 16 |
sentinel surveillance | 16 |
pb gene | 16 |
novel coronavirus | 16 |
influenza vii | 16 |
infected mice | 16 |
vaccine development | 16 |
imported cases | 16 |
protective equipment | 16 |
puerto rico | 16 |
domestic poultry | 16 |
ns protein | 16 |
specific igy | 16 |
allantoic fluid | 16 |
antigenic changes | 16 |
acid changes | 16 |
nucleotide sequences | 16 |
novel swine | 16 |
viral co | 16 |
human infection | 16 |
ha cleavage | 16 |
frequently detected | 16 |
household contacts | 16 |
per year | 16 |
organ culture | 16 |
aerosol transmission | 16 |
reactive antibody | 16 |
noninvasive ventilation | 16 |
rsv infection | 16 |
united kingdom | 16 |
richards model | 16 |
european countries | 16 |
antigenic characterization | 16 |
saudi arabia | 16 |
peripheral blood | 15 |
early influenza | 15 |
new york | 15 |
primary health | 15 |
geometric mean | 15 |
pathogens detected | 15 |
alveolar epithelial | 15 |
rrt pcrs | 15 |
lao pdr | 15 |
drug resistance | 15 |
previously reported | 15 |
face masks | 15 |
virus circulation | 15 |
phylogenetic analyses | 15 |
virus type | 15 |
rt rt | 15 |
vaccination rates | 15 |
risk factor | 15 |
northern hemisphere | 15 |
patients presenting | 15 |
reproduction numbers | 15 |
hemagglutination inhibition | 15 |
great britain | 15 |
swine flu | 15 |
respiratory illnesses | 15 |
lung tissue | 15 |
national health | 15 |
viral etiologies | 15 |
pandemic strains | 15 |
inactivated vaccine | 15 |
well plates | 15 |
receptor binding | 15 |
darby canine | 15 |
described previously | 15 |
hospitalization data | 15 |
resplex ii | 15 |
determine whether | 15 |
pandemic flu | 15 |
small number | 15 |
molecular assays | 15 |
human rhinoviruses | 15 |
odds ratios | 15 |
based surveillance | 15 |
low pathogenic | 15 |
sandwich elisa | 15 |
hours post | 15 |
statistical significance | 15 |
second vaccination | 15 |
gene sequences | 15 |
nasal swab | 15 |
pandemic viruses | 15 |
ns gene | 14 |
observational studies | 14 |
available data | 14 |
infected patients | 14 |
among patients | 14 |
human lung | 14 |
rapid antigen | 14 |
antigenic sites | 14 |
adult patients | 14 |
blackwell publishing | 14 |
strain selection | 14 |
healthcare settings | 14 |
data analysis | 14 |
respiratory pathogen | 14 |
wild ducks | 14 |
vaccine strains | 14 |
recent studies | 14 |
experimentally infected | 14 |
vaccine composition | 14 |
publishing ltd | 14 |
confirmed ph | 14 |
viral coinfection | 14 |
previous reports | 14 |
one patient | 14 |
virus vaccine | 14 |
supporting information | 14 |
prospective study | 14 |
viruses may | 14 |
diagnostic sensitivity | 14 |
tracheal explants | 14 |
gene segment | 14 |
antiviral resistance | 14 |
vaccination rate | 14 |
xtd tm | 14 |
bacterial pneumonia | 14 |
poultry markets | 14 |
mask group | 14 |
lung injury | 14 |
adenovirus type | 14 |
immune system | 14 |
genetic reassortment | 14 |
table shows | 14 |
pandemic planning | 14 |
community cohort | 14 |
bacterial pathogens | 14 |
mask use | 14 |
migratory birds | 14 |
regression model | 14 |
amino acids | 14 |
health research | 14 |
even though | 14 |
current study | 14 |
preventive measures | 13 |
laboratory confirmed | 13 |
side effects | 13 |
south africa | 13 |
infectious agents | 13 |
clinical information | 13 |
data collection | 13 |
term care | 13 |
fatal cases | 13 |
viral titers | 13 |
acid substitutions | 13 |
many countries | 13 |
severe illness | 13 |
medical care | 13 |
rgy sub | 13 |
clinical trial | 13 |
treated mice | 13 |
infectious virus | 13 |
critically ill | 13 |
molecular techniques | 13 |
symptomatic cases | 13 |
wide range | 13 |
reassortant viruses | 13 |
european sivs | 13 |
immunized mice | 13 |
please cite | 13 |
endothelial cells | 13 |
one virus | 13 |
pandemic scenario | 13 |
plaque assay | 13 |
wild type | 13 |
gene expression | 13 |
associated hospitalizations | 13 |
weekly ph | 13 |
detection limit | 13 |
confidence intervals | 13 |
turning points | 13 |
sensing receptors | 13 |
classical reassortment | 13 |
full genome | 13 |
initial rrt | 13 |
tissue culture | 13 |
protective immunity | 13 |
average number | 13 |
first time | 13 |
infectious dose | 13 |
mortality rate | 13 |
viral mono | 13 |
ae years | 13 |
laboratory diagnoses | 13 |
rhinovirus infection | 13 |
monoclonal antibodies | 13 |
household incidence | 13 |
room temperature | 13 |
personal protective | 13 |
previously published | 12 |
influenza neuraminidase | 12 |
invasive mv | 12 |
human coronaviruses | 12 |
infection cases | 12 |
vaccine manufacturers | 12 |
single infection | 12 |
latent period | 12 |
time points | 12 |
swine viruses | 12 |
written informed | 12 |
pcr diagnosis | 12 |
hospital admission | 12 |
clinical severity | 12 |
one dose | 12 |
first pandemic | 12 |
specimens collected | 12 |
neutralizing antibodies | 12 |
iav infection | 12 |
throat swab | 12 |
prior protection | 12 |
control chart | 12 |
underlying conditions | 12 |
multiple viral | 12 |
relative humidity | 12 |
results show | 12 |
case fatality | 12 |
retrospective study | 12 |
victoria lineage | 12 |
much higher | 12 |
wt virus | 12 |
rgvac ins | 12 |
version ae | 12 |
human population | 12 |
acute lung | 12 |
viral agents | 12 |
study population | 12 |
clinical outcomes | 12 |
neuraminidase assay | 12 |
older adults | 12 |
nasopharyngeal aspirates | 12 |
multiplex rt | 12 |
ad hoc | 12 |
different countries | 12 |
innate sensing | 12 |
health authorities | 12 |
two assays | 12 |
syncytial viruses | 12 |
ill patients | 12 |
diagnostic tests | 12 |
exponential growth | 12 |
mechanical ventilation | 12 |
virus evolution | 12 |
virus subtypes | 12 |
generation time | 12 |
vaccine groups | 12 |
chart method | 12 |
may lead | 12 |
antigenic variants | 12 |
mycoplasma pneumoniae | 12 |
positive rate | 12 |
domestic ducks | 12 |
triple reassortant | 12 |
binding specificity | 12 |
hospital admissions | 12 |
also observed | 12 |
randomized trial | 12 |
erk activation | 12 |
virus strain | 12 |
commonly detected | 12 |
primary human | 12 |
older age | 12 |
entry screening | 12 |
serial intervals | 12 |
hi antibody | 12 |
cytokine chemokine | 12 |
virus gene | 12 |
healthy controls | 12 |
results showed | 12 |
associated influenza | 11 |
red blood | 11 |
second dose | 11 |
transmission model | 11 |
study also | 11 |
two pathogens | 11 |
common viruses | 11 |
different subtypes | 11 |
ah pdm | 11 |
limited number | 11 |
mice infected | 11 |
immunotherapy program | 11 |
winter season | 11 |
chronic illness | 11 |
severe infections | 11 |
hi titres | 11 |
sunshine duration | 11 |
respiratory mucosa | 11 |
vietnamese children | 11 |
disease surveillance | 11 |
placebo group | 11 |
signaling pathways | 11 |
epidemic curves | 11 |
leading cause | 11 |
serial dilutions | 11 |
host immune | 11 |
will help | 11 |
infected human | 11 |
study showed | 11 |
selective cox | 11 |
recent study | 11 |
cell line | 11 |
hpiv type | 11 |
phylogenetic trees | 11 |
ii cells | 11 |
cellular immune | 11 |
new virus | 11 |
like illnesses | 11 |
poyang lake | 11 |
early warning | 11 |
fit testing | 11 |
coronavirus nl | 11 |
decision making | 11 |
patients hospitalized | 11 |
virus lineages | 11 |
may provide | 11 |
mini kit | 11 |
maximum likelihood | 11 |
tested using | 11 |
information regarding | 11 |
two doses | 11 |
genetic changes | 11 |
influenza antigenic | 11 |
analysis showed | 11 |
genome sequences | 11 |
tract samples | 11 |
first imported | 11 |
infection among | 11 |
natural history | 11 |
generated using | 11 |
ambulance dispatch | 11 |
school aged | 11 |
significant increases | 11 |
research agenda | 11 |
coverage rates | 11 |
prevent influenza | 11 |
asymptomatic carriers | 11 |
single viral | 11 |
significantly reduced | 11 |
first vaccination | 11 |
east asia | 11 |
inhibition assay | 11 |
migratory waterfowl | 11 |
mortality rates | 11 |
findings suggest | 11 |
fatality rate | 11 |
receptor specificity | 11 |
symptomatic transmission | 11 |
currently circulating | 11 |
epidemiological information | 11 |
bronchiolitis severity | 11 |
multiple infections | 11 |
oseltamivir carboxylate | 11 |
missing data | 11 |
rgvac sub | 11 |
old embryonated | 11 |
inflammatory response | 11 |
ili data | 11 |
viruses using | 11 |
one study | 11 |
antiviral agents | 11 |
lung tissues | 11 |
basic reproduction | 11 |
large number | 11 |
increased severity | 11 |
lung disease | 11 |
school children | 11 |
human airway | 11 |
better understanding | 11 |
specimen collection | 11 |
bird markets | 11 |
hai antibody | 11 |
genetic characterization | 11 |
virus titer | 11 |
also found | 11 |
mouse model | 10 |
th century | 10 |
reverse primer | 10 |
live poultry | 10 |
studies conducted | 10 |
data collected | 10 |
viruses belonging | 10 |
viral na | 10 |
sectional study | 10 |
pathogen pairs | 10 |
see table | 10 |
among health | 10 |
working group | 10 |
culture medium | 10 |
wave richards | 10 |
plaque assays | 10 |
coxiella burnetii | 10 |
different age | 10 |
inflammatory cytokines | 10 |
statistically different | 10 |
haemophilus influenzae | 10 |
will continue | 10 |
mask wearing | 10 |
random effect | 10 |
case definitions | 10 |
viral antigen | 10 |
key points | 10 |
host response | 10 |
haemagglutination inhibition | 10 |
guinea pigs | 10 |
nasal discharge | 10 |
high sensitivity | 10 |
children admitted | 10 |
software version | 10 |
response rate | 10 |
young adults | 10 |
viral pneumonia | 10 |
aged children | 10 |
randomly selected | 10 |
nasal wash | 10 |
vaccine candidate | 10 |
resistant influenza | 10 |
time interval | 10 |
positive cases | 10 |
less sensitive | 10 |
influenza cases | 10 |
ari onset | 10 |
na activity | 10 |
strains isolated | 10 |
first years | 10 |
total rna | 10 |
also showed | 10 |
conducted using | 10 |
pandemic alert | 10 |
nuclear translocation | 10 |
pigs infected | 10 |
russian federation | 10 |
increased risk | 10 |
antigenic site | 10 |
also tested | 10 |
least two | 10 |
bacterial mono | 10 |
statistical analyses | 10 |
inactivated vaccines | 10 |
donor percentage | 10 |
virus epidemics | 10 |
diagnostic agreement | 10 |
taken together | 10 |
cell proliferation | 10 |
health workers | 10 |
human adenovirus | 10 |
viral strains | 10 |
transmission rate | 10 |
mitigation measures | 10 |
pcr positive | 10 |
infected children | 10 |
severe pneumonia | 10 |
cm protein | 10 |
information may | 10 |
medical records | 10 |
mean proportion | 10 |
research institute | 10 |
better understand | 10 |
specific siga | 10 |
virus yield | 10 |
critical care | 10 |
duck populations | 10 |
local case | 10 |
exact test | 10 |
minor poultry | 10 |
risk assessment | 10 |
molecular epidemiology | 10 |
specific cd | 10 |
risk groups | 10 |
embryonated eggs | 10 |
lpai viruses | 10 |
airway epithelium | 10 |
type i | 10 |
virus shedding | 10 |
day pi | 10 |
time period | 10 |
risk procedures | 10 |
asian countries | 10 |
post infection | 10 |
subtype influenza | 10 |
cov infection | 10 |
sari case | 10 |
aquatic birds | 10 |
drinking water | 10 |
mus tlr | 10 |
blood cultures | 10 |
moving average | 10 |
oseltamivir treatment | 10 |
pseudomonas aeruginosa | 10 |
early phase | 10 |
ns genes | 10 |
copy number | 10 |
basic amino | 10 |
tract disease | 10 |
well plate | 10 |
type virus | 10 |
european union | 10 |
multivariable analysis | 10 |
prior immunity | 10 |
mrna splicing | 10 |
intranasal administration | 10 |
three viruses | 10 |
contact ferrets | 10 |
vaccination campaign | 10 |
mass vaccination | 9 |
attack rates | 9 |
patients aged | 9 |
first case | 9 |
vaccine administration | 9 |
epidemiological data | 9 |
samples tested | 9 |
control strategies | 9 |
influenza control | 9 |
human serum | 9 |
research topics | 9 |
pcr products | 9 |
body temperature | 9 |
one hundred | 9 |
virus interactions | 9 |
year old | 9 |
potential role | 9 |
randomized clinical | 9 |
clinical diagnosis | 9 |
detected viruses | 9 |
clinical manifestations | 9 |
slightly higher | 9 |
new pandemic | 9 |
influenza outbreak | 9 |
hai antibodies | 9 |
times higher | 9 |
cluster randomized | 9 |
genome sequencing | 9 |
rsv infections | 9 |
rt pcr | 9 |
younger age | 9 |
ae mg | 9 |
observed among | 9 |
na inhibitor | 9 |
common cold | 9 |
pcr rt | 9 |
mean proportions | 9 |
laboratory data | 9 |
original clinical | 9 |
health surveillance | 9 |
specific mrna | 9 |
antiviral efficacy | 9 |
matrix gene | 9 |
like receptor | 9 |
controlled trial | 9 |
early findings | 9 |
several studies | 9 |
seasonal strains | 9 |
assay using | 9 |
log eid | 9 |
hpiv types | 9 |
antiviral coating | 9 |
health service | 9 |
dual infections | 9 |
institutional review | 9 |
surgical mask | 9 |
basic reproductive | 9 |
review board | 9 |
additional supporting | 9 |
absorbance values | 9 |
antigen tests | 9 |
blood cells | 9 |
compared using | 9 |
information criterion | 9 |
asthma exacerbations | 9 |
clinical isolates | 9 |
clinical course | 9 |
face mask | 9 |
risk communication | 9 |
influenza viral | 9 |
air conditioning | 9 |
stool samples | 9 |
type ii | 9 |
multiple sequence | 9 |
using real | 9 |
influenza rapid | 9 |
absolute humidity | 9 |
multiple pathogens | 9 |
tissue specimens | 9 |
live bird | 9 |
randomised controlled | 9 |
virus vaccines | 9 |
pcr testing | 9 |
aged less | 9 |
chemokine profiles | 9 |
seasonal patterns | 9 |
first local | 9 |
chlamydophila psittaci | 9 |
calculated using | 9 |
demographic data | 9 |
priority public | 9 |
health topics | 9 |
data obtained | 9 |
close contacts | 9 |
severe lower | 9 |
na inhibitors | 9 |
na subtypes | 9 |
global pandemic | 9 |
sporadic cases | 9 |
model predictions | 9 |
novel virus | 9 |
pathogenic influenza | 9 |
febrile respiratory | 9 |
treatment coverage | 9 |
general hospital | 9 |
regional laboratories | 9 |
odds ratio | 9 |
pcr system | 9 |
suspected cases | 9 |
pex treatment | 9 |
picu group | 9 |
pdm pandemic | 9 |
detect influenza | 9 |
specific primers | 9 |
south wales | 9 |
competing interests | 9 |
binding site | 9 |
among influenza | 9 |
community acquired | 9 |
viral pathogen | 9 |
cytokine profiles | 9 |
antibiotic treatment | 9 |
subjects vaccinated | 9 |
avian flu | 9 |
also investigated | 9 |
annual influenza | 9 |
high level | 9 |
glycosylation sites | 9 |
control arm | 9 |
influenza activity | 9 |
nucleic acids | 9 |
monoclonal antibody | 9 |
probe set | 9 |
communicable diseases | 9 |
pandemic period | 9 |
multivariate logistic | 9 |
neuraminidase inhibition | 9 |
clinical significance | 9 |
medical research | 9 |
descriptive statistics | 9 |
antiviral therapy | 9 |
three times | 9 |
time polymerase | 9 |
sialic acid | 9 |
insulated isothermal | 9 |
ari group | 9 |
three waves | 9 |
asymptomatic infections | 9 |
many studies | 9 |
virus production | 9 |
three groups | 9 |
ferrets infected | 9 |
flu infections | 9 |
cov patients | 9 |
ambulance dispatches | 9 |
atypical bacterial | 9 |
pandemic response | 9 |
time cell | 9 |
care staff | 9 |
step rt | 9 |
new south | 9 |
aerosolized viral | 9 |
lg ha | 9 |
simulation model | 9 |
southeast asia | 9 |
influenza detection | 9 |
widely used | 9 |
chlamydophila pneumoniae | 9 |
avian viruses | 9 |
another study | 9 |
virus ha | 9 |
specific antibodies | 9 |
temporal model | 9 |
blood cell | 8 |
randomized controlled | 8 |
diagnostic testing | 8 |
hi titers | 8 |
will provide | 8 |
six internal | 8 |
binding preference | 8 |
archived tissue | 8 |
comparative epidemiology | 8 |
pharmaceutical substances | 8 |
different influenza | 8 |
clinical respiratory | 8 |
runny nose | 8 |
reduced susceptibility | 8 |
bocavirus infection | 8 |
suspect cases | 8 |
ph ae | 8 |
case number | 8 |
less likely | 8 |
blood culture | 8 |
post hoc | 8 |
influenza illness | 8 |
ha titres | 8 |
coverage rate | 8 |
hand washing | 8 |
surface glycoproteins | 8 |
virus isolated | 8 |
laboratory isolates | 8 |
target cells | 8 |
infected individuals | 8 |
mask arm | 8 |
will also | 8 |
authors declare | 8 |
partial protection | 8 |
pathogen detected | 8 |
infectious period | 8 |
five markets | 8 |
sequence alignment | 8 |
onset date | 8 |
threat posed | 8 |
one respiratory | 8 |
clinical study | 8 |
mean ic | 8 |
duck species | 8 |
virus titration | 8 |
community transmission | 8 |
old female | 8 |
asymptomatic children | 8 |
one time | 8 |
average viral | 8 |
new rat | 8 |
elderly population | 8 |
hospitalized infants | 8 |
transmission events | 8 |
derived reassortants | 8 |
cell surface | 8 |
reassortant virus | 8 |
onset dates | 8 |
hospitalization duration | 8 |
nucleotide sequence | 8 |
research council | 8 |
nasal congestion | 8 |
parameter estimates | 8 |
serum hai | 8 |
first cases | 8 |
genetic diversity | 8 |
adverse effects | 8 |
get vaccinated | 8 |
poultry species | 8 |
influenza antigen | 8 |
small proportion | 8 |
ct value | 8 |
significant association | 8 |
air interface | 8 |
camel contact | 8 |
including influenza | 8 |
global burden | 8 |
underlying immunosuppressive | 8 |
normalized absorbance | 8 |
percent agreement | 8 |
remains unclear | 8 |
hygiene measures | 8 |
commonly used | 8 |
estimated reproduction | 8 |
disease symptoms | 8 |
circulating strains | 8 |
viral detection | 8 |
antiviral activity | 8 |
health protection | 8 |
assay kit | 8 |
age distribution | 8 |
considered significant | 8 |
using spss | 8 |
vaccine coverage | 8 |
low reactors | 8 |
experimental studies | 8 |
bead clearance | 8 |
viruses including | 8 |
viral mrna | 8 |
elderly people | 8 |
value ae | 8 |
emerging influenza | 8 |
influenza disease | 8 |
human infections | 8 |
respiratory secretions | 8 |
controlled trials | 8 |
naturally acquired | 8 |
coronavirus infection | 8 |
preventing influenza | 8 |
like virus | 8 |
single infections | 8 |
influenza type | 8 |
potential confounders | 8 |
antibody titres | 8 |
human pandemic | 8 |
ha sequences | 8 |
antiviral intervention | 8 |
new protocol | 8 |
virus challenge | 8 |
fold lower | 8 |
hhs regions | 8 |
death data | 8 |
virus hemagglutinin | 8 |
cytoplasmic tail | 8 |
accession numbers | 8 |
like lineage | 8 |
study subjects | 8 |
influenza among | 8 |
scientific evidence | 8 |
mucosal immunity | 8 |
two viruses | 8 |
second wave | 8 |
na mutations | 8 |
studies showed | 8 |
hai assay | 8 |
high mortality | 8 |
severe clinical | 8 |
virus disease | 8 |
uninfected cells | 8 |
blood donors | 8 |
analyzed using | 8 |
year period | 8 |
disease progression | 8 |
coronavirus disease | 8 |
mean age | 8 |
demographic characteristics | 8 |
described elsewhere | 8 |
disease signs | 8 |
serological studies | 8 |
diagnostic methods | 8 |
seasonal human | 8 |
children human | 8 |
multiplex reverse | 8 |
low rank | 8 |
reference viruses | 8 |
hubei province | 8 |
low level | 8 |
publicly available | 8 |
widespread use | 8 |
atypical bacteria | 8 |
ae among | 8 |
developed countries | 8 |
natural hosts | 8 |
sentinel hospitals | 8 |
cdc protocol | 8 |
coated respirators | 8 |
blown specimens | 8 |
first study | 8 |
tract illness | 8 |
aluminum hydroxide | 8 |
year prospective | 8 |
eurasian avian | 8 |
bacterial co | 8 |
low levels | 8 |
highly sensitive | 8 |
cases identified | 8 |
final version | 8 |
joining method | 8 |
interspecies transmission | 8 |
data available | 8 |
culture supernatants | 8 |
pcr amplification | 8 |
reported previously | 8 |
previous study | 8 |
study may | 8 |
guinea pig | 8 |
recombinant strain | 8 |
positive results | 8 |
blood service | 8 |
control study | 8 |
adjuvanted clade | 8 |
proinflammatory cytokines | 8 |
research ethics | 8 |
vaccinated animals | 8 |
flow cytometry | 8 |
human health | 8 |
high levels | 8 |
pediatric patients | 8 |
vp sequences | 8 |
vaccination hi | 8 |
ae nm | 8 |
female balb | 8 |
pdm influenza | 8 |
inoculated intranasally | 8 |
viral isolates | 8 |
animal health | 7 |
seasonal flu | 7 |
ha titer | 7 |
case report | 7 |
collaborating centres | 7 |
detection methods | 7 |
provide evidence | 7 |
virus containing | 7 |
infections caused | 7 |
determined using | 7 |
fecal droppings | 7 |
distinct lineages | 7 |
community settings | 7 |
assays using | 7 |
various organs | 7 |
par agonists | 7 |
early diagnosis | 7 |
evoc system | 7 |
swabs collected | 7 |
three patients | 7 |
environmental factors | 7 |
viruses within | 7 |
ha genes | 7 |
catalogue number | 7 |
cartography construction | 7 |
group compared | 7 |
monitoring influenza | 7 |
chemiluminescent assays | 7 |
health response | 7 |
viral growth | 7 |
data suggest | 7 |
influenza centres | 7 |
culture system | 7 |
preclinical testing | 7 |
endothelial cell | 7 |
current vaccine | 7 |
cleavage motif | 7 |
pathogens among | 7 |
future studies | 7 |
close contact | 7 |
early stage | 7 |
virus antigen | 7 |
cytokine induction | 7 |
patients may | 7 |
environmental specimens | 7 |
also used | 7 |
first year | 7 |
australian government | 7 |
seroprotection rates | 7 |
duck population | 7 |
foster city | 7 |
adults hospitalized | 7 |
serfling method | 7 |
mean concentration | 7 |
especially among | 7 |
staff members | 7 |
mathematical models | 7 |
patients treated | 7 |
acute viral | 7 |
large numbers | 7 |
ic kit | 7 |
transport medium | 7 |
multiple infection | 7 |
acid sequences | 7 |
hospital outbreak | 7 |
host range | 7 |
elisa method | 7 |
contemporary european | 7 |
epidemic period | 7 |
influenza infected | 7 |
viruses causing | 7 |
shorter recovery | 7 |
adaptive immunity | 7 |
results obtained | 7 |
low prevalence | 7 |
next influenza | 7 |
reassortant swine | 7 |
infectious latent | 7 |
time quantitative | 7 |
study influenza | 7 |
first report | 7 |
recommendation system | 7 |
methods used | 7 |
clade ae | 7 |
gene sequence | 7 |
infectious viruses | 7 |
coated respirator | 7 |
virus pandemic | 7 |
much lower | 7 |
data presented | 7 |
ae sd | 7 |
neutralizing antibody | 7 |
pandemic vaccines | 7 |
rna segment | 7 |
positive control | 7 |
detection kit | 7 |
emergency departments | 7 |
animal model | 7 |
viral genome | 7 |
molecular evolutionary | 7 |
resistant seasonal | 7 |
influenza positive | 7 |
chronic conditions | 7 |
evidence base | 7 |
household members | 7 |
drug susceptibility | 7 |
per day | 7 |
bronchial epithelial | 7 |
asymptomatic infection | 7 |
suitable vaccine | 7 |
hypogammaglobulinemia patients | 7 |
commonly identified | 7 |
diagnosis delay | 7 |
provided free | 7 |
pharmaceutical interventions | 7 |
initial case | 7 |
analytical sensitivity | 7 |
longer recovery | 7 |
recombinant viruses | 7 |
individuals aged | 7 |
human disease | 7 |
immunomodulatory agents | 7 |
vaccination policy | 7 |
illness severity | 7 |
schlieren imaging | 7 |
single dose | 7 |
study provides | 7 |
care facility | 7 |
rapid detection | 7 |
based influenza | 7 |
coronavirus infections | 7 |
epithelial surface | 7 |
study found | 7 |
osv cam | 7 |
binding properties | 7 |
health policy | 7 |
clinical outcome | 7 |
study participants | 7 |
mathematical modelling | 7 |
par stimulation | 7 |
cross protection | 7 |
early transmission | 7 |
respiratory epithelial | 7 |
pulmonary disease | 7 |
bacterial coinfection | 7 |
kong sar | 7 |
ciliated cells | 7 |
multicenter retrospective | 7 |
ae mm | 7 |
prevent transmission | 7 |
clinical presentations | 7 |
temporal mc | 7 |
sentinel general | 7 |
productive infection | 7 |
clinical presentation | 7 |
laboratory diagnosis | 7 |
serum specimens | 7 |
epidemic influenza | 7 |
using primers | 7 |
correlation coefficient | 7 |
master donor | 7 |
viruses among | 7 |
study included | 7 |
pulmonary exacerbation | 7 |
contract hhsn | 7 |
two distinct | 7 |
patients suspected | 7 |
gastrointestinal symptoms | 7 |
kindly provided | 7 |
immune protection | 7 |
meteorological parameters | 7 |
pilot study | 7 |
neuraminidase activity | 7 |
gene constellation | 7 |
mortality associated | 7 |
rank mc | 7 |
mallard ducks | 7 |
intervention measures | 7 |
rna segments | 7 |
fit test | 7 |
icu admissions | 7 |
seasonal epidemic | 7 |
animal models | 7 |
acute bronchiolitis | 7 |
underlying comorbidities | 7 |
surveillance network | 7 |
following vaccination | 7 |
first influenza | 7 |
analysis found | 7 |
studies used | 7 |
similar results | 7 |
hi assay | 7 |
chickens inoculated | 7 |
probably due | 7 |
virus circulating | 7 |
high rate | 7 |
infections due | 7 |
influenza patients | 7 |
late stage | 7 |
virological surveillance | 7 |
clinical recovery | 7 |
positive pigs | 7 |
epidemic data | 7 |
serum antibody | 7 |
acid residues | 7 |
igv domain | 7 |
ped group | 7 |
two patients | 7 |
cambodian np | 7 |
apoptotic response | 7 |
oropharyngeal swabs | 7 |
rhinovirus species | 7 |
human cells | 7 |
tissue samples | 7 |
antibody titre | 7 |
us centers | 7 |
higher prevalence | 7 |
virus surveillance | 7 |
improving influenza | 7 |
international health | 7 |
i i | 7 |
hai test | 7 |
inactivated whole | 7 |
reported cases | 7 |
influenza scenario | 7 |
early stages | 7 |
published studies | 7 |
disease virus | 7 |
health agencies | 7 |
genetic analysis | 7 |
existing immunity | 7 |
cloacal swabs | 7 |
qpcr detection | 7 |
data set | 7 |
single virus | 7 |
post inoculation | 7 |
immunocompromised patients | 7 |
eastern china | 7 |
evolutionary genomics | 7 |
hypogammaglobulinemic patients | 7 |
novel pandemic | 7 |
st century | 7 |
virus stocks | 7 |
time course | 7 |
younger children | 7 |
influenza strain | 7 |
surgical masks | 7 |
effective reproduction | 7 |
host factors | 7 |
clinical illness | 6 |
high growth | 6 |
infected experimentally | 6 |
three consecutive | 6 |
virus showed | 6 |
regional office | 6 |
detecting influenza | 6 |
immunocompromised children | 6 |
intervention arms | 6 |
using specific | 6 |
will support | 6 |
pharyngeal swabs | 6 |
surveillance study | 6 |
sera collected | 6 |
different strains | 6 |
results indicated | 6 |
different respiratory | 6 |
virus used | 6 |
transcriptase pcr | 6 |
infection patterns | 6 |
inhibitor resistance | 6 |
high viral | 6 |
primary case | 6 |
enrolled patients | 6 |
described earlier | 6 |
washed twice | 6 |
systematic reviews | 6 |
specific viruses | 6 |
molecular markers | 6 |
hospital setting | 6 |
significant role | 6 |
national surveillance | 6 |
eligibility criteria | 6 |
chest pain | 6 |
related swine | 6 |
viral mrnas | 6 |
rsv xc | 6 |
positive result | 6 |
second immunization | 6 |
erk pathway | 6 |
ae hours | 6 |
osv group | 6 |
geographic cartography | 6 |
quantitative rt | 6 |
laboratory confirmation | 6 |
community surveillance | 6 |
seroprevalence rates | 6 |
wang respiratory | 6 |
test results | 6 |
patient care | 6 |
last years | 6 |
virological data | 6 |
estimated using | 6 |
cytokine expression | 6 |
progenitor identification | 6 |
study suggests | 6 |
winter influenza | 6 |
two studies | 6 |
rv ev | 6 |
combined immunodeficiency | 6 |
ha peptide | 6 |
negative controls | 6 |
cl specimens | 6 |
performed according | 6 |
reduce transmission | 6 |
distance matrix | 6 |
symptoms onset | 6 |
rna viruses | 6 |
bacterial pathogen | 6 |
monopathogen patients | 6 |
egyptian pilgrims | 6 |
turnaround time | 6 |
live influenza | 6 |
epidemiological analysis | 6 |
four different | 6 |
viruses tested | 6 |
transplant recipients | 6 |
infected lung | 6 |
vaccine uptake | 6 |
influenza pathogenesis | 6 |
tracheal swabs | 6 |
epidemiological characteristics | 6 |
inactivated virus | 6 |
transmission parameters | 6 |
square test | 6 |
nat positive | 6 |
relatively small | 6 |
intestinal tract | 6 |
high throughput | 6 |
phase i | 6 |
well known | 6 |
emerging respiratory | 6 |
genetic variation | 6 |
among adults | 6 |
singapore military | 6 |
severe combined | 6 |
showed high | 6 |
using standard | 6 |
previous findings | 6 |
hospital level | 6 |
infected animals | 6 |
influenza preparedness | 6 |
versicolor spores | 6 |
provide protection | 6 |
epidemic situations | 6 |
confirmed human | 6 |
respiratory conditions | 6 |
year olds | 6 |
allow us | 6 |
inhibition assays | 6 |
increased levels | 6 |
hbov infections | 6 |
donor strain | 6 |
antibiotic therapy | 6 |
viral proteins | 6 |
sterilizing immunity | 6 |
climate factors | 6 |
novel genotypes | 6 |
early occurrence | 6 |
settling chamber | 6 |
reassortant influenza | 6 |
th week | 6 |
virus cm | 6 |
antiviral effect | 6 |
newly identified | 6 |
collected within | 6 |
family size | 6 |
matrix completion | 6 |
healthy adults | 6 |
current understanding | 6 |
institut pasteur | 6 |
mean average | 6 |
getting vaccinated | 6 |
frequent detection | 6 |
viral transport | 6 |
glycosylation site | 6 |
pandemic risk | 6 |
transmission characteristics | 6 |
two different | 6 |
new human | 6 |
egg isolates | 6 |
every year | 6 |
received tiv | 6 |
naturally resistant | 6 |
high prevalence | 6 |
virus dilutions | 6 |
nitric oxide | 6 |
surveillance studies | 6 |
index cases | 6 |
tympanic temperature | 6 |
isolation rates | 6 |
white mice | 6 |
study using | 6 |
hypoxemic respiratory | 6 |
highly conserved | 6 |
induce apoptosis | 6 |
virus outbreak | 6 |
proposed passive | 6 |
molecular evolution | 6 |
multiple viruses | 6 |
ion channel | 6 |
later waves | 6 |
na sequences | 6 |
june th | 6 |
first identified | 6 |
results indicate | 6 |
studies will | 6 |
ns mrna | 6 |
tm influenza | 6 |
influenza research | 6 |
dual respiratory | 6 |
investigation team | 6 |
cells infected | 6 |
winter months | 6 |
viral isolation | 6 |
peptides derived | 6 |
analysis revealed | 6 |
epidemiological surveillance | 6 |
analysis using | 6 |
tissue homogenates | 6 |
oral infection | 6 |
exposed subjects | 6 |
avg cusum | 6 |
int csr | 6 |
small sample | 6 |
isolated viruses | 6 |
master mix | 6 |
poultry traded | 6 |
lethal infection | 6 |
air pollutants | 6 |
dynamic range | 6 |
prevention strategies | 6 |
dual resistant | 6 |
trial id | 6 |
study aimed | 6 |
nyambari market | 6 |
cell signaling | 6 |
preliminary results | 6 |
cytokine dysregulation | 6 |
health concern | 6 |
blown nasal | 6 |
exit screening | 6 |
series analysis | 6 |
fold dilutions | 6 |
patients without | 6 |
significance level | 6 |
swab samples | 6 |
total siga | 6 |
epidemic growth | 6 |
airborne influenza | 6 |
regression method | 6 |
tween ae | 6 |
adaptive immune | 6 |
defined influenza | 6 |
archived tissues | 6 |
two major | 6 |
allows us | 6 |
shed virus | 6 |
fold higher | 6 |
donor virus | 6 |
light emission | 6 |
respiratory score | 6 |
healthcare providers | 6 |
aged care | 6 |
human parvovirus | 6 |
better protection | 6 |
cell tropism | 6 |
around ae | 6 |
administration costs | 6 |
university hospital | 6 |
roche flx | 6 |
less severe | 6 |
amongst cambodian | 6 |
hai tests | 6 |
higher proportions | 6 |
kidney cells | 6 |
infection using | 6 |
symptomatic case | 6 |
novel human | 6 |
bovine serum | 6 |
study designs | 6 |
specific pathogen | 6 |
age range | 6 |
children years | 6 |
gene pool | 6 |
culture infectious | 6 |
onset week | 6 |
univariate analysis | 6 |
monovalent vaccine | 6 |
rapid peer | 6 |
published data | 6 |
done using | 6 |
little information | 6 |
recently reported | 6 |
school closures | 6 |
readily available | 6 |
control methods | 6 |
ari cases | 6 |
primary cases | 6 |
cell responses | 6 |
additional respiratory | 6 |
mice treated | 6 |
subtype viruses | 6 |
medium supplemented | 6 |
ferrets inoculated | 6 |
data sets | 6 |
infection dose | 6 |
ec values | 6 |
practice staff | 6 |
weeks later | 6 |
infectious virions | 6 |
observational study | 6 |
case patient | 6 |
avian species | 6 |
also shows | 6 |
years ago | 6 |
respiratory diseases | 6 |
ethical approval | 6 |
strains circulating | 6 |
global surveillance | 6 |
virus pb | 6 |
medical conditions | 6 |
serially diluted | 6 |
hospital hcws | 6 |
winter holidays | 6 |
policy makers | 6 |
influenza hospitalizations | 6 |
evolutionary genetics | 6 |
clinical studies | 6 |
cell viability | 6 |
specific antibody | 6 |
laboratory results | 6 |
sensitivity analysis | 6 |
office hours | 6 |
based study | 6 |
ns proteins | 6 |
clinical management | 6 |
viral fitness | 6 |
bacterial colonisation | 6 |
aerosolized influenza | 6 |
following conditions | 6 |
significant implications | 6 |
also obtained | 6 |
vp gene | 6 |
specific real | 6 |
human cell | 6 |
molecular screening | 6 |
phylogenetic tree | 6 |
porto alegre | 6 |
negative control | 6 |
disease caused | 6 |
mean body | 6 |
immunosuppressive conditions | 6 |
children presenting | 6 |
richards models | 6 |
nl infection | 6 |
inflammatory responses | 6 |
ae units | 6 |
mean ae | 6 |
health interventions | 6 |
imported case | 6 |
genetic variability | 6 |
future antigenic | 6 |
surveillance program | 6 |
new viruses | 6 |
potential pandemic | 6 |
seroprotection rate | 6 |
vaccine based | 6 |
significant increase | 6 |
transfected cells | 6 |
assay sensitivity | 6 |
metapneumovirus infection | 6 |
epidemiological study | 6 |
different settings | 6 |
influenza hospitalization | 6 |
chart review | 6 |
genetics analysis | 6 |
air sacs | 6 |
final concentration | 6 |
analysed strains | 6 |
one case | 6 |
recombinant protein | 6 |
communityacquired pneumonia | 6 |
detailed data | 6 |
molecular detection | 6 |
previous report | 6 |
sentinel practitioners | 6 |
laboratory tests | 6 |
values obtained | 6 |
ic determination | 6 |
children younger | 6 |
antibody titer | 6 |
similar across | 6 |
protein content | 6 |
influenza progenitor | 6 |
viral protein | 6 |
coronavirus hku | 6 |
neu aca | 6 |
chronic diseases | 6 |
prospective studies | 6 |
pig herds | 6 |
sporadic human | 6 |
investigated whether | 6 |
virus activity | 6 |
phylogenetic methods | 6 |
adverse events | 6 |
biosafety level | 6 |
tcid assay | 6 |
studies suggest | 6 |
bioaerosol samplers | 6 |
rhinovirus outbreak | 6 |
hi test | 6 |
reported elsewhere | 6 |
rapid diagnosis | 6 |
higher incidence | 6 |
considered positive | 6 |
standard error | 6 |
relatively low | 6 |
weeks ending | 6 |
matrix protein | 6 |
bacterial coinfections | 6 |
annual epidemics | 6 |
laboratory capacity | 6 |
virus growth | 6 |
ae lgeid | 6 |
foreseeable future | 6 |
human volunteers | 6 |
assays provide | 6 |
virus rna | 6 |
longer time | 6 |
respiratory rate | 6 |
also considered | 6 |
pr virus | 6 |
lung lesions | 6 |
nucleotide substitution | 6 |
challenge studies | 6 |
ae eid | 6 |
staphylococcus aureus | 6 |
genetically related | 6 |
paediatric intensive | 6 |
resistant variants | 6 |
control mice | 6 |
general practices | 6 |
children detection | 6 |
human research | 5 |
patients compared | 5 |
reaction assay | 5 |
serologic assays | 5 |
particle size | 5 |
university grants | 5 |
rapid diagnostic | 5 |
peak period | 5 |
susceptible cells | 5 |
higher proportion | 5 |
adults admitted | 5 |
fungal spores | 5 |
pressure ventilation | 5 |
ml tree | 5 |
seropositive proportion | 5 |
detection rates | 5 |
may suggest | 5 |
affected individuals | 5 |
ili rate | 5 |
summer holiday | 5 |
water samples | 5 |
sampling time | 5 |
intranasal pathogenicity | 5 |
pandemic mortality | 5 |
lung infection | 5 |
close proximity | 5 |
family physicians | 5 |
seasonal viruses | 5 |
drastically reduced | 5 |
patients years | 5 |
dual infection | 5 |
hcws willing | 5 |
cough etiquette | 5 |
earlier studies | 5 |
seasonal trends | 5 |
genome sequence | 5 |
wet markets | 5 |
human alveolar | 5 |
base case | 5 |
clinical evaluation | 5 |
swine tracheal | 5 |
new respiratory | 5 |
containing ae | 5 |
mers patients | 5 |
seasonal variation | 5 |
included two | 5 |
otitis media | 5 |
viral quantification | 5 |
raina macintyre | 5 |
microneutralization assays | 5 |
thank dr | 5 |
western blotting | 5 |
ari hospitalization | 5 |
lymphocyte count | 5 |
plasma membrane | 5 |
one viral | 5 |
qualified cell | 5 |
year study | 5 |
influenza respiratory | 5 |
radiology findings | 5 |
containment phase | 5 |
past pandemics | 5 |
transmission rates | 5 |
requiring medical | 5 |
lumped demand | 5 |
transmission within | 5 |
future pandemic | 5 |
viral titer | 5 |
holy week | 5 |
nasopharyngeal samples | 5 |
clinical impact | 5 |
vaccine group | 5 |
pulmonary exacerbations | 5 |
virus propagation | 5 |
included studies | 5 |
standard curves | 5 |
antiviral susceptibility | 5 |
cytopathic effects | 5 |
influenza seasonality | 5 |
records system | 5 |
poultry population | 5 |
fattening farms | 5 |
inflammation status | 5 |
viral strain | 5 |
showed similar | 5 |
may contribute | 5 |
mediated immunity | 5 |
positively correlated | 5 |
pcr using | 5 |
virus may | 5 |
laboratory surveillance | 5 |
new method | 5 |
negative results | 5 |
global alert | 5 |
gmt ae | 5 |
response system | 5 |
standard procedures | 5 |
two trials | 5 |
vaccine technologies | 5 |
body weights | 5 |
hi matrix | 5 |
general public | 5 |
fatal respiratory | 5 |
wave model | 5 |
study group | 5 |
minh city | 5 |
mice injected | 5 |
mortem materials | 5 |
fifty percent | 5 |
index monitoring | 5 |
health regulations | 5 |
following infection | 5 |
previously infected | 5 |
average weekly | 5 |
rsv bronchiolitis | 5 |
conducted amongst | 5 |
viral particle | 5 |
health emergency | 5 |
adapted viruses | 5 |
following virus | 5 |
uncoated ffp | 5 |
data concerning | 5 |
blood sample | 5 |
nosocomial transmission | 5 |
antibiotic use | 5 |
statistical software | 5 |
shell vial | 5 |
severely ill | 5 |
virologically confirmed | 5 |
wash samples | 5 |
two human | 5 |
standard method | 5 |
clinical use | 5 |
systematic sampling | 5 |
sas institute | 5 |
model parameters | 5 |
domestic waterfowl | 5 |
study conducted | 5 |
adults aged | 5 |
target groups | 5 |
health intervention | 5 |
hospitalised children | 5 |
virus outbreaks | 5 |
birth cohort | 5 |
primary schools | 5 |
demographic information | 5 |
vp region | 5 |
people aged | 5 |
rural areas | 5 |
york city | 5 |
humoral inflammation | 5 |
clinical sample | 5 |
influenza influenza | 5 |
na enzyme | 5 |
different species | 5 |
control animals | 5 |
also significantly | 5 |
respiratory specimen | 5 |
goat anti | 5 |
significant reduction | 5 |
full length | 5 |
molecular characterization | 5 |
np gene | 5 |
modern tools | 5 |
monte carlo | 5 |
sc treated | 5 |
hospitalization rate | 5 |
induces protective | 5 |
pcr kit | 5 |
molecular diagnostic | 5 |
lethality rate | 5 |
results will | 5 |
th cells | 5 |
influenza samples | 5 |
hemisphere influenza | 5 |
challenge virus | 5 |
melting curve | 5 |
three dimensional | 5 |
stranded rna | 5 |
viruses used | 5 |
discrepant results | 5 |
dna polymerase | 5 |
domestic duck | 5 |
geographic specific | 5 |
using sas | 5 |
hemisphere winter | 5 |
study revealed | 5 |
influenza spread | 5 |
hoc sampling | 5 |
hierarchical clustering | 5 |
immunocompromising conditions | 5 |
vaccine showed | 5 |
subjects born | 5 |
specific immune | 5 |
healthy children | 5 |
seasonal distribution | 5 |
weekly virological | 5 |
type viruses | 5 |
lung microvascular | 5 |
regulatory authorities | 5 |
volunteer challenge | 5 |
model fit | 5 |
time point | 5 |
chi minh | 5 |
disease prevention | 5 |
yield reassortants | 5 |
study protocol | 5 |
hbov strains | 5 |
clearance assay | 5 |
clear seasonality | 5 |
pcr detection | 5 |
cell types | 5 |
data showed | 5 |
fully susceptible | 5 |
dependent manner | 5 |
circulating virus | 5 |
ae ci | 5 |
abnormal radiology | 5 |
individual virus | 5 |
van asten | 5 |
pandemic threat | 5 |
studies using | 5 |
five priority | 5 |
wide variety | 5 |
rural thailand | 5 |
essential medium | 5 |
different levels | 5 |
authors thank | 5 |
ipd meta | 5 |
viruses emerged | 5 |
universal influenza | 5 |
second part | 5 |
unusual severity | 5 |
onto antigenic | 5 |
following criteria | 5 |
cytokine levels | 5 |
practice nurses | 5 |
higher rate | 5 |
also reported | 5 |
respective viral | 5 |
negative patients | 5 |
based transmission | 5 |
improve clinical | 5 |
dendritic cells | 5 |
higher sensitivity | 5 |
corrected post | 5 |
plate format | 5 |
early epidemic | 5 |
vaccine supply | 5 |
considered statistically | 5 |
plasmapheresis capacity | 5 |
two vaccine | 5 |
provide data | 5 |
organ cultures | 5 |
relatively early | 5 |
viral causes | 5 |
rhinovirus enterovirus | 5 |
patients methods | 5 |
ha subtypes | 5 |
vaccine efficacy | 5 |
cov outbreak | 5 |
inpatient department | 5 |
culture technique | 5 |
contact patterns | 5 |
cambodian vp | 5 |
success rate | 5 |
enhanced surveillance | 5 |
vaccination programs | 5 |
grant aoe | 5 |
positive percent | 5 |
significant morbidity | 5 |
cell immunoglobulin | 5 |
organ failure | 5 |
serious illness | 5 |
different time | 5 |
reactive protein | 5 |
eurasian lineage | 5 |
mononuclear cells | 5 |
seasonal vaccine | 5 |
negative correlation | 5 |
care setting | 5 |
pooled analysis | 5 |
random sampling | 5 |
quality control | 5 |
progenitor genes | 5 |
wild aquatic | 5 |
reporting delays | 5 |
american avian | 5 |
high incidence | 5 |
early treatment | 5 |
local public | 5 |
may become | 5 |
online version | 5 |
chronic disease | 5 |
spss inc | 5 |
enterovirus rhinovirus | 5 |
also performed | 5 |
spread rapidly | 5 |
outbreak investigation | 5 |
registered ili | 5 |
vaccine dose | 5 |
two weeks | 5 |
using data | 5 |
core team | 5 |
microscopic observation | 5 |
development core | 5 |
sensitive detection | 5 |
period distribution | 5 |
getting sick | 5 |
risk patients | 5 |
trivalent inactivated | 5 |
microvascular endothelial | 5 |
global health | 5 |
control ferrets | 5 |
demand parameter | 5 |
sentinel network | 5 |
less susceptible | 5 |
highly attenuated | 5 |
consistently lower | 5 |
molecular diagnosis | 5 |
china date | 5 |
additional information | 5 |
national research | 5 |
generic detection | 5 |
epidemiologic year | 5 |
exhaled airflows | 5 |
age category | 5 |
medical services | 5 |
identify potential | 5 |
genetics derived | 5 |
must also | 5 |
behavioral responses | 5 |
showed significantly | 5 |
proct values | 5 |
control guidelines | 5 |
cd ifnc | 5 |
viral nucleoprotein | 5 |
susceptibility testing | 5 |
study implementation | 5 |
oseltamivir prophylaxis | 5 |
mix hybrid | 5 |
virological records | 5 |
based studies | 5 |
physical interventions | 5 |
limited data | 5 |
human subjects | 5 |
median value | 5 |
mean titers | 5 |
influenza sentinel | 5 |
rate among | 5 |
proct levels | 5 |
generation interval | 5 |
antigen assay | 5 |
individuals infected | 5 |
unexplained pneumonia | 5 |
potency testing | 5 |
derived influenza | 5 |
young age | 5 |
previous exposure | 5 |
cytokine production | 5 |
increased susceptibility | 5 |
nt assays | 5 |
vla regional | 5 |
sentinel sites | 5 |
antigenic variation | 5 |
approximately ae | 5 |
hemisphere countries | 5 |
viral suspension | 5 |
positive bacterial | 5 |
sequences obtained | 5 |
among school | 5 |
virus laboratory | 5 |
east asian | 5 |
ciliary activity | 5 |
stop solution | 5 |
negative binomial | 5 |
paediatric ari | 5 |
incidence rate | 5 |
respiratory tissues | 5 |
veterinary laboratories | 5 |
data show | 5 |
epidemic activity | 5 |
multiple logistic | 5 |
time intervals | 5 |
outcome measures | 5 |
human populations | 5 |
conventional rt | 5 |
economic burden | 5 |
antigen detection | 5 |
literature review | 5 |
secondary infection | 5 |
np protein | 5 |
mucosal immunization | 5 |
quantitative real | 5 |
infections detected | 5 |
qinghai lake | 5 |
suspension cell | 5 |
generating procedures | 5 |
secondary attack | 5 |
influenza immunization | 5 |
surveillance period | 5 |
vascular dysfunction | 5 |
gel electrophoresis | 5 |
influenza diagnosis | 5 |
sari surveillance | 5 |
emergency medical | 5 |
detected among | 5 |
emergency room | 5 |
seasonal peak | 5 |
higher vaccination | 5 |
data using | 5 |
us cdc | 5 |
mn assays | 5 |
relative risk | 5 |
data support | 5 |
new technologies | 5 |
egg production | 5 |
transmitted infections | 5 |
new therapeutic | 5 |
identified outside | 5 |
intranasal route | 5 |
low viral | 5 |
viruses will | 5 |
hospitalized vietnamese | 5 |
second week | 5 |
pigs per | 5 |
family members | 5 |
eight patients | 5 |
virus induced | 5 |
detailed information | 5 |
ectopic trypsin | 5 |
mortality worldwide | 5 |
circulating cytokine | 5 |
simple method | 5 |
cases may | 5 |
old chickens | 5 |
trial comparing | 5 |
vaccination program | 5 |
also shown | 5 |
sao paulo | 5 |
pilgrims returning | 5 |
reference strains | 5 |
peak titers | 5 |
pig populations | 5 |
recently published | 5 |
rna isolation | 5 |
amongst hospitalised | 5 |
mild symptoms | 5 |
initial human | 5 |
randomised trial | 5 |
short time | 5 |
schlieren images | 5 |
obstructive pulmonary | 5 |
khanh hoa | 5 |
aerosol particles | 5 |
sampling strategy | 5 |
virus induces | 5 |
respiratory season | 5 |
median duration | 5 |
different laboratories | 5 |
new jersey | 5 |
proinflammatory cytokine | 5 |
acute hypoxemic | 5 |
human virus | 5 |
egg infectious | 5 |
admission length | 5 |
nursing home | 5 |
developed using | 5 |
realtime pcr | 5 |
infection amongst | 5 |
ili surveillance | 5 |
fourth wave | 5 |
emerging infectious | 5 |
infections associated | 5 |
legionella pneumophila | 5 |
amongst children | 5 |
mitigation strategies | 5 |
reactive antibodies | 5 |
multivariable logistic | 5 |
severe human | 5 |
also included | 5 |
last decade | 5 |
specific diagnosis | 5 |
microcentrifuge tubes | 5 |
important implications | 5 |
ho chi | 5 |
hospital health | 5 |
excellence scheme | 5 |
positive blood | 5 |
cluster primary | 5 |
multiple respiratory | 5 |
took place | 5 |
cytokine responses | 5 |
legal guardians | 5 |
cluster secondary | 5 |
respiratory outbreaks | 5 |
protection hypothesis | 5 |
categorical variables | 5 |
neurosurgical inpatient | 5 |
developed severe | 5 |
data interpretation | 5 |
south korea | 5 |
nhs organisations | 5 |
pulmonary function | 5 |
illness among | 5 |
reproduction ratio | 5 |
patient visits | 5 |
viruses published | 5 |
higher ha | 5 |
vaccine doses | 5 |
sequence alignments | 5 |
wild waterfowl | 5 |
major risk | 5 |
immunoglobulin mucin | 5 |
whereas others | 5 |
children hospitalised | 5 |
laboratory animals | 5 |
financial support | 5 |
confirmed mers | 5 |
central region | 5 |
trial found | 5 |
standardized questionnaire | 5 |
pandemic laiv | 5 |
na subtype | 5 |
blood mononuclear | 5 |
highest urgency | 5 |
bayesian information | 5 |
particularly important | 5 |
epidemic peak | 5 |
cusum method | 5 |
immunization programs | 5 |
among seasonal | 5 |
growth kinetics | 5 |
red cross | 5 |
care units | 5 |
infections occurred | 5 |
writing group | 5 |
collected data | 5 |
nai distribution | 5 |
one child | 5 |
yamagata lineage | 5 |
tested arm | 5 |
genbank accession | 5 |
metabolic conditions | 5 |
fecal swabs | 5 |
nine hospitals | 5 |
daily basis | 5 |
also detected | 5 |
several respiratory | 5 |
viral panel | 5 |
extracted using | 5 |
zealand data | 5 |
hospital workers | 5 |
research roadmap | 5 |